EU/3/21/2553: Orphan designation for the treatment of spinocerebellar ataxia

Troriluzole hydrochloride

Table of contents


This medicine was designated as an orphan medicine for the treatment of spinocerebellar ataxia in the European Union on 10 December 2021.

This means that the developer will receive scientific and regulatory support from EMA to advance their medicine to the stage where they can apply for a marketing authorisation.

Orphan designation does not mean the medicine is available or authorised for use. All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.

During the medicine's development, doctors may be able to enrol patients in clinical trials investigating the medicine. For information on ongoing clinical trials in the EU, see:

Key facts

Active substance
Troriluzole hydrochloride
Intended use
Treatment of spinocerebellar ataxia
Orphan designation status
EU designation number
Date of designation

Biohaven Bioscience Ireland Limited
6th Floor
South Bank House
Barrow Street
Dublin 4 D04 TR29



Update history

May 2023The sponsorship was transferred from Biohaven Pharmaceutical Ireland DAC, Ireland to Biohaven Bioscience Ireland Limited, Ireland. 

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating
1 rating
1 rating